Comment on An International Multicenter, Retrospective Cohort Study of 203 Patients with Pediatric Androgenetic Alopecia
April 2025
in “
Journal of the American Academy of Dermatology
”

TLDR The study has limitations, and future research should use better methods to improve treatment for children with hair loss.
The commentary on the study of 203 pediatric patients with androgenetic alopecia highlights several limitations that affect the study's validity and clinical applicability. Concerns include the use of off-label treatments like finasteride and minoxidil, with finasteride potentially disrupting androgen-dependent development in children. The study's short follow-up period and reliance on subjective assessments may underestimate adverse effects and overestimate treatment efficacy. Additionally, the study's retrospective design and lack of standardized protocols limit the assessment of metabolic comorbidities. Future research should focus on prospective studies with standardized protocols and consider genetic, metabolic, and environmental factors to improve treatment strategies and outcomes for children with androgenetic alopecia.